{"id":32842,"date":"2025-02-11T16:37:55","date_gmt":"2025-02-11T13:37:55","guid":{"rendered":"https:\/\/massivebio.com\/?p=32842"},"modified":"2025-05-27T14:33:29","modified_gmt":"2025-05-27T11:33:29","slug":"massive-bio-accelerating-cancer-research-amid-nih-funding","status":"publish","type":"post","link":"https:\/\/massivebio.com\/massive-bio-accelerating-cancer-research-amid-nih-funding\/","title":{"rendered":"Massive Bio Stands Committed to Accelerating Cancer Research and Clinical Trial Access Amid NIH Funding Uncertainty"},"content":{"rendered":"

NEW YORK, February 11, 2025<\/strong> \u2013 A sweeping shift in federal policy\u2014capped, at least temporarily, by a federal judge\u2019s decision to halt the NIH\u2019s proposed 15% indirect cost rate\u2014has brought unprecedented turmoil to the biomedical research community. Despite this legal reprieve for 22 states, experts say the structural impact on research costs, staffing, and operational models could be long-lasting. Today, Massive Bio reaffirms its steadfast commitment to bridging gaps in cancer research and ensuring every patient has equal access to cutting-edge clinical trials.<\/p>\n

As an organization founded with an SBIR NIH\/NCI grant to develop a patient-centric, AI-driven Deep Learning Clinical Trial Matching System (DLCTMS, also known as Synergy-AI<\/a>)<\/strong>, Massive Bio has always been dedicated to leveling the playing field in clinical trials. Our technology-driven platform helps connect cancer patients to the studies that best match their condition\u2014rapidly, accurately, and at scale. In this time of widespread uncertainty, Massive Bio pledges to expand collaborations with research centers, academic institutions, community clinics, and government agencies to sustain momentum in the face of budgetary flux.<\/p>\n

\u201cAs we navigate this uncharted territory in federal research funding, our mission remains crystal clear: Cancer patients need timely, equitable access to promising new therapies,\u201d<\/em> said Dr. Arturo Loaiza-Bonilla<\/a>, Co-Founder and Chief Medical Officer of Massive Bio. \u201cAt Massive Bio, we stand ready to leverage our platform, forging partnerships that preserve trial enrollment rates, expedite FDA reviews, and ensure essential innovations continue\u2014no matter the administrative climate.\u201d<\/em><\/p>\n

A significant portion of clinical research has traditionally centered on major academic cancer hubs. Recent events highlight the necessity of diversification and decentralization: shifting more studies and investigative capabilities to community-based practices, closer to patients\u2019 everyday lives. Massive Bio\u2019s approach aligns perfectly with this new reality, offering digitally enabled pre-screening and immediate patient-trial matching tools that streamline clinical research outside the traditional large hospital framework.<\/p>\n

\u201cIt was truly a day to remember with the NIH\u2019s abrupt reduction of indirect cost rates\u2014compounded by reports of FDA staffing cuts that could slow new drug approvals,\u201d<\/em> said Selin Kurnaz<\/a>, Co-Founder and CEO of Massive Bio<\/strong>. \u201cBut one thing never changes: Cancer patients deserve access to the latest clinical trials and treatments. In this challenging environment, we see an opportunity to rethink how clinical research is conducted in the U.S., from decentralizing study sites to embracing modern technology. We\u2019ve worked relentlessly to bring clinical trials closer to community practices, and these evolving policies only underscore why that mission matters more than ever. We are ready. Are you?\u201d<\/em><\/p>\n

In addition to collaborative outreach with established NCI-designated centers, Massive Bio\u2019s model empowers community practitioners, many of whom lack extensive resources to support trial logistics. With further emphasis on telemedicine and remote monitoring, the company seeks to reduce geographic and socioeconomic barriers\u2014a critical step toward equitable health care. Ultimately, this approach aims to preserve scientific rigor while managing costs and ensuring faster enrollments, thereby benefiting patients, sponsors, and research teams alike.<\/p>\n

Call to Action<\/h2>\n
    \n
  • Research Institutions & Cancer Centers:<\/strong> Partner with Massive Bio to maintain or even increase patient enrollment in clinical trials.<\/li>\n
  • Community Clinics & Physicians:<\/strong> Leverage Massive Bio\u2019s streamlined trial-matching and remote consent solutions, ensuring patients can access cutting-edge therapies closer to home.<\/li>\n
  • Pharmaceutical & Biotech Sponsors:<\/strong> Collaborate with Massive Bio to optimize trial operations, enhance recruitment, and meet key milestones\u2014despite ongoing financial uncertainties.<\/li>\n
  • Policymakers & Government Agencies:<\/strong> Work with Massive Bio to operationalize cost-effective, tech-driven solutions that protect America\u2019s leadership in cancer research.<\/li>\n<\/ul>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/section>\n","protected":false},"excerpt":{"rendered":"NEW YORK, February 11, 2025 \u2013 A sweeping shift in federal policy\u2014capped, at least temporarily, by a federal judge\u2019s decision to halt the NIH\u2019s proposed 15% indirect cost rate\u2014has brought unprecedented turmoil to the biomedical research community. Despite this legal reprieve for 22 states, experts say the structural impact on research costs, staffing, and operational...","protected":false},"author":11,"featured_media":32843,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55],"tags":[],"class_list":["post-32842","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en"],"yoast_head":"\nMassive Bio Stands Committed to Accelerating Cancer Research and Clinical Trial Access Amid NIH Funding Uncertainty<\/title>\n<meta name=\"description\" content=\"As an organization founded with an SBIR NIH\/NCI grant to develop a patient-centric, AI-driven Deep Learning Clinical Trial Matching System (DLCTMS, also known as Synergy-AI).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/massivebio.com\/massive-bio-accelerating-cancer-research-amid-nih-funding\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Massive Bio Stands Committed to Accelerating Cancer Research and Clinical Trial Access Amid NIH Funding Uncertainty %\" \/>\n<meta property=\"og:description\" content=\"As an organization founded with an SBIR NIH\/NCI grant to develop a patient-centric, AI-driven Deep Learning Clinical Trial Matching System (DLCTMS, also known as Synergy-AI).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/massivebio.com\/massive-bio-accelerating-cancer-research-amid-nih-funding\/\" \/>\n<meta property=\"og:site_name\" content=\"Massive Bio\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/facebook.com\/people\/Massive-Bio-As\/100094663612187\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-11T13:37:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-27T11:33:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/02\/massivebio-pr.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"767\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sinan Gul\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MassiveBio\" \/>\n<meta name=\"twitter:site\" content=\"@MassiveBio\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sinan Gul\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Massive Bio Stands Committed to Accelerating Cancer Research and Clinical Trial Access Amid NIH Funding Uncertainty","description":"As an organization founded with an SBIR NIH\/NCI grant to develop a patient-centric, AI-driven Deep Learning Clinical Trial Matching System (DLCTMS, also known as Synergy-AI).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/massivebio.com\/massive-bio-accelerating-cancer-research-amid-nih-funding\/","og_locale":"en_US","og_type":"article","og_title":"Massive Bio Stands Committed to Accelerating Cancer Research and Clinical Trial Access Amid NIH Funding Uncertainty %","og_description":"As an organization founded with an SBIR NIH\/NCI grant to develop a patient-centric, AI-driven Deep Learning Clinical Trial Matching System (DLCTMS, also known as Synergy-AI).","og_url":"https:\/\/massivebio.com\/massive-bio-accelerating-cancer-research-amid-nih-funding\/","og_site_name":"Massive Bio","article_publisher":"https:\/\/facebook.com\/people\/Massive-Bio-As\/100094663612187\/","article_published_time":"2025-02-11T13:37:55+00:00","article_modified_time":"2025-05-27T11:33:29+00:00","og_image":[{"width":1024,"height":767,"url":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/02\/massivebio-pr.webp","type":"image\/webp"}],"author":"Sinan Gul","twitter_card":"summary_large_image","twitter_creator":"@MassiveBio","twitter_site":"@MassiveBio","twitter_misc":{"Written by":"Sinan Gul","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/massivebio.com\/massive-bio-accelerating-cancer-research-amid-nih-funding\/#article","isPartOf":{"@id":"https:\/\/massivebio.com\/massive-bio-accelerating-cancer-research-amid-nih-funding\/"},"author":{"name":"Sinan Gul","@id":"https:\/\/massivebio.com\/#\/schema\/person\/961d749445523a588f7ffb7086d037c6"},"headline":"Massive Bio Stands Committed to Accelerating Cancer Research and Clinical Trial Access Amid NIH Funding Uncertainty","datePublished":"2025-02-11T13:37:55+00:00","dateModified":"2025-05-27T11:33:29+00:00","mainEntityOfPage":{"@id":"https:\/\/massivebio.com\/massive-bio-accelerating-cancer-research-amid-nih-funding\/"},"wordCount":610,"publisher":{"@id":"https:\/\/massivebio.com\/#organization"},"image":{"@id":"https:\/\/massivebio.com\/massive-bio-accelerating-cancer-research-amid-nih-funding\/#primaryimage"},"thumbnailUrl":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/02\/massivebio-pr.webp","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/massivebio.com\/massive-bio-accelerating-cancer-research-amid-nih-funding\/","url":"https:\/\/massivebio.com\/massive-bio-accelerating-cancer-research-amid-nih-funding\/","name":"Massive Bio Stands Committed to Accelerating Cancer Research and Clinical Trial Access Amid NIH Funding Uncertainty","isPartOf":{"@id":"https:\/\/massivebio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/massivebio.com\/massive-bio-accelerating-cancer-research-amid-nih-funding\/#primaryimage"},"image":{"@id":"https:\/\/massivebio.com\/massive-bio-accelerating-cancer-research-amid-nih-funding\/#primaryimage"},"thumbnailUrl":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/02\/massivebio-pr.webp","datePublished":"2025-02-11T13:37:55+00:00","dateModified":"2025-05-27T11:33:29+00:00","description":"As an organization founded with an SBIR NIH\/NCI grant to develop a patient-centric, AI-driven Deep Learning Clinical Trial Matching System (DLCTMS, also known as Synergy-AI).","breadcrumb":{"@id":"https:\/\/massivebio.com\/massive-bio-accelerating-cancer-research-amid-nih-funding\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/massivebio.com\/massive-bio-accelerating-cancer-research-amid-nih-funding\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/massivebio.com\/massive-bio-accelerating-cancer-research-amid-nih-funding\/#primaryimage","url":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/02\/massivebio-pr.webp","contentUrl":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/02\/massivebio-pr.webp","width":1024,"height":767,"caption":"massivebio pr"},{"@type":"BreadcrumbList","@id":"https:\/\/massivebio.com\/massive-bio-accelerating-cancer-research-amid-nih-funding\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Homepage","item":"https:\/\/massivebio.com\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/massivebio.com\/resources\/news-en\/"},{"@type":"ListItem","position":3,"name":"Massive Bio Stands Committed to Accelerating Cancer Research and Clinical Trial Access Amid NIH Funding Uncertainty"}]},{"@type":"WebSite","@id":"https:\/\/massivebio.com\/#website","url":"https:\/\/massivebio.com\/","name":"Cancer Analysis and Clinical Trial Matching","description":"Best Oncology Advisory Services By Cancer Treatment Care Specialists & Tumor Board Experts in America","publisher":{"@id":"https:\/\/massivebio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/massivebio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/massivebio.com\/#organization","name":"Massive Bio","url":"https:\/\/massivebio.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/massivebio.com\/#\/schema\/logo\/image\/","url":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/01\/Massive-Bio-Logo-Circle.svg","contentUrl":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/01\/Massive-Bio-Logo-Circle.svg","width":"1024","height":"1024","caption":"Massive Bio"},"image":{"@id":"https:\/\/massivebio.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/facebook.com\/people\/Massive-Bio-As\/100094663612187\/","https:\/\/x.com\/MassiveBio","https:\/\/instagram.com\/massive_bio\/","https:\/\/tiktok.com\/@massivebio","https:\/\/youtube.com\/massivebio"],"email":"support@massivebio.com","legalName":"Massive Bio"},{"@type":"Person","@id":"https:\/\/massivebio.com\/#\/schema\/person\/961d749445523a588f7ffb7086d037c6","name":"Sinan Gul"}]}},"_links":{"self":[{"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/posts\/32842","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/comments?post=32842"}],"version-history":[{"count":3,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/posts\/32842\/revisions"}],"predecessor-version":[{"id":35563,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/posts\/32842\/revisions\/35563"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/media\/32843"}],"wp:attachment":[{"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/media?parent=32842"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/categories?post=32842"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/tags?post=32842"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}